Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma.

已完结 10 由 Michael 发布于 2026/6/25 9:12:45

DOI:10.1056/NEJMoa2024257
作者：Michael E Wechsler,?Marcella K Ruddy,?Ian D Pavord,?Elliot Israel,?Klaus F Rabe,?Linda B Ford,?Jorge F Maspero,?Raolat M Abdulai,?Chih-Chi Hu,?Renata Martincova,?Andreas Jessel,?Michael C Nivens,?Nikh
文献类型：期刊论文
补充材料：只需要正文

New England Journal of Medicine (NEJM)

Abstract：Background: Monoclonal antibodies targeting IgE, interleukin-4 and -13, and interleukin-5 are effective in treating severe type 2 asthma, but new targets are needed. Itepekimab is a new mono

应助信息

7小时前

tao33

84651375703311f1a23b34735aa3bc31.pdf 已采纳

8小时前

Book学术机器人

2026/6/25 9:12:45 未找到该文献，机器人已退出，请等待人工下载

2026/6/25 9:12:45 Book学术AI机器人收到请求，开始寻找文献

2026/6/25 9:12:45 已向机器人发送请求

8小时前

Michael 发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:SageImpact of continuous renal replacement therapy and Cytosorb on cefiderocol pharmacokinetics: "One size does not fit all".